Key terms
About SUPN
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SUPN news
May 01
8:37am ET
Supernus partners with Busy Philipps to shine spotlight on ADHD in women
Apr 15
7:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
Apr 08
8:03am ET
Supernus: FDA says SPN-830 NDA ‘not ready for approval’ in present form
Feb 28
5:22pm ET
Supernus Pharmaceuticals Enhances Executive Compensation Packages
Feb 28
7:31am ET
Piper Sandler Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
Feb 28
7:25am ET
Supernus price target lowered to $41 from $45 at Piper Sandler
Feb 27
8:15pm ET
Strong Buy for Supernus Pharmaceuticals on Qelbree’s Robust Sales Growth and Positive Market Outlook
Feb 27
4:36pm ET
Supernus sees 2024 revenue $580M-$620M, consensus $622.52M
Feb 27
4:35pm ET
Supernus reports Q4 EPS 2c, consensus 40c
Feb 15
9:03am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 06
4:35am ET
Supernus Pharmaceuticals Wins Patent Infringement Lawsuit
Feb 05
8:32am ET
Supernus wins infringement, validity case on Trokendi XR against Torrent
SUPN Financials
Key terms
Ad Feedback
SUPN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SUPN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range